The cost-effectiveness of intermittent preventive treatment for malaria in infants in Sub-Saharan Africa

PLoS ONE

Volumn 5, Issue 6, 2010, Pages

  Conteh, Lesong ^a,j   Sicuri, Elisa ^b,c   Manzi, Fatuma ^d   Hutton, Guy ^a   Obonyo, Benson ^e   Tediosi, Fabrizio ^a,f   Biao, Prosper ^g   Masika, Paul ^h   Matovu, Fred ⁱ   Otieno, Peter ^e   Gosling, Roly D ^j   Hame, Mary ^e,k   Odhiambo, Frank O ^e   Grobusch, Martin P ^l,m,n   Kremsner, Peter G ^m,n   Chandramohan, Daniel ^j   Aponte, John J ^b,o   Egan, Andrea ^b   Schellenberg, David ^j   Macete, Eusebio ^o   Slutsker, Laurence ^j   Newman, Robert D ^j   Alonso, Pedro ^b,c,o   Menéndez, Clara ^b,c,o   Tanner, Marcel ^a   more..

^a SWISS TROPICAL AND PUBLIC HEALTH INSTITUTE   (Switzerland)

^b UNIVERSITY OF BARCELONA   (Spain)

^c CIBER EPIDEMIOLOGÍA Y SALUD PÚBLICA CIBERESP   (Spain)

^d IFAKARA HEALTH INSTITUTE   (Tanzania)

^e KENYA MEDICAL RESEARCH INSTITUTE   (Kenya)

^f University of Boconni   (Italy)

^g National Institute for Medical Research ^*

^h NATIONAL INSTITUTE FOR MEDICAL RESEARCH   (Tanzania)

ⁱ MAKERERE UNIVERSITY   (Uganda)

^j LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^k CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^l ALBERT SCHWEITZER HOSPITAL   (Gabon)

^m UNIVERSITY OF THE WITWATERSRAND   (South Africa)

ⁿ UNIVERSITY OF TÜBINGEN   (Germany)

^o Ministérioda Saúde   (Mozambique)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AMODIAQUINE PLUS ARTESUNATE; ARTESUNATE; CHLORPROGUANIL PLUS DAPSONE; FANSIDAR; MEFLOQUINE;

AFRICA; ARTICLE; CLINICAL TRIAL; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG EFFICACY; FATALITY; HEALTH CARE COST; HEALTH CARE DELIVERY; HEALTH CARE SYSTEM; HUMAN; INCIDENCE; INFANT; KENYA; MALARIA; MALARIA CONTROL; TANZANIA;

AFRICA SOUTH OF THE SAHARA; ANTIMALARIALS; COST-BENEFIT ANALYSIS; DRUG COMBINATIONS; HUMANS; INFANT; MALARIA; PYRIMETHAMINE; SULFADOXINE;

ARTESUNATE;

EID: 77956222768     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0010313     Document Type: Article

References (62)

1. WHO (2008) World Malaria Report 2008.
2. Egan A, Crawley J, Schellenberg D (2005) Intermittent preventive treatment for malaria control in infants: moving towards evidence-based policy and public health action. Tropical Medicine and International Health 10: 815-817.
3. Grobusch MP, Egan A, Gosling RD, Newman RD (2007) Intermittent preventive therapy for malaria: progress and future directions. Current Opinion in Infectious Diseases 20: 613-620.
4. Aponte JJ, Schellenberg D, Egan A, Breckenridge A, Carneiro I, et al. (2009) Efficacy and safety of intermittent preventive treatment with sulfadoxine-pyrimethamine for malaria in African infants: a pooled analysis of six randomised, placebo-controlled trials. The Lancet 374: 1533-1542.
5. Gosling R, Gesase S, Mosha J, Carneiro I, Hashim R, et al. (2009) Protective efficacy and safety of three antimalarial regimens for intermittent preventive treatment for malaria in infants: a randomised, placebo-controlled trial. The Lancet 374: 1521-1532.
6. Odhiambo FO, Hamel MJ, Williamson J, Lindblade K, ter Kuile FO, et al. (2010) Intermittent Preventive Treatment in Infants for the Prevention of Malaria in Rural Western Kenya: A Randomized, Double-Blind Placebo-Controlled Trial. PLoS ONE 5(4): e10016. doi:10.1371/journal.pone.0010016.
7. Manzi F, Hutton G, Schellenberg J, Tanner M, Alsono P, et al. (2008) From strategy development to routine implementation: the cost of Intermittent Preventive Treatment in Infants for malaria control. BMC Health Services Research 8:
8. Manzi F, Schellenberg J, Hamis Y, Mushi AK, Shirima K, et al. (2009) Intermittent preventive treatment for malaria and anaemia control in Tanzanian infants; the development and implementation of a public health strategy. Transactions of the Royal Society of Tropical Medicine and Hygiene 103: 79-86.
9. Mushi A, Schellenberg J, Mrisho M, Manzi F, Mbuya C, et al. (2008) Development of behaviour change communication strategy for a vaccination-linked malaria control tool in southern Tanzania. Malar J 7: 191.
10. Pool R, Munguambe K, Macete E, Aide P, Juma G, et al. (2006) Community response to intermittent preventive treatment delivered to infants (IPTi) through the EPI system in Manhiça, Mozambique. Trop Med Int Health 11: 1670-1678.
11. Pool R, Mushi A, Armstrong Schellenberg J, Mrisho M, Alonso P, et al. (2008) The acceptability of intermittent preventive treatment of malaria in infants (IPTi) delivered through the expanded programme of immunization in southern Tanzania. Malar J 7: 213.
12. Hutton G, Schellenberg D, Tediosi F, Macete E, Kahigwa E, et al. (2009) Cost-effectiveness of malaria intermittent preventive treatment in infants (IPTi) in Mozambique and the United Republic of Tanzania. Bulletin of the World Health Organisation 87: 123-129.
13. Schellenberg D, Menendez C, Kahigwa E, Aponte J, Vidal J, et al. (2001) Intermittent treatment for malaria and anaemia control at time of routine vaccinations in Tanzanian infants: a randomised, placebo-controlled trial. The Lancet 357: 1471-1477.
14. Macete E, Aide P, Aponte J, Sanz S, Mandomando I, et al. (2006) Intermittent Preventive Treatment for Malaria Control Administered at the Time of Routine Vaccinations in Mozambican Infants: A Randomized, Placebo Controlled Trial. JID 194: 276-285.
15. Grobusch MP, Lell B, Schwarz NG, Gabor J, Dornemann J, et al. (2007) Intermittent Preventive Treatment against Malaria in Infants in Gabon-A Randomized, Double-Blind, Placebo-Controlled Trial. JID 196: 1595.
16. Mockenhaupt FP, Reither K, Zanger P, Roepcke F, Danquah I, et al. (2007) Intermittent Preventive Treatment in Infants as a Means of Malaria Control: a Randomized, Double-Blind, Placebo-Controlled Trial in Northern Ghana. Antimicrobial Agents and Chemotherepy 51: 3273-3281.
17. Kobbe R, Kreuzberg C, Adjei S, Thompson B, Langefeld I, et al. (2007) A Randomized Controlled Trial of Extended Intermittent Preventive Antimalarial Treatment in Infants. Clinical Infectious Diseases 45: 16-25.
18. Chandramohan D, Owusu-Agyei S, Carneiro I, Awine T, Amponsa-Achiano K, et al. (2005) Cluster randomised trial of intermittent preventive treatment for malaria in infants in area of high, seasonal transmission in Ghana. BMJ 331: 727-733.
19. Kweku M, Liu D, Adjuik M, Binka F, Seidu M, et al. (2008) Seasonal Intermittent Preventive Treatment for the Prevention of Anaemia and Malaria in Ghanaian Children: A Randomized, Placebo Controlled Trial. PLoS ONE 3: e4000.
20. Anand S, Hanson K (1997) Disability-adjusted life years: a critical review. Journal of Health Economics 16:
21. Murray C (1994) Quantifying the burden of disease: the technical basis for disability adjusted life years. Bulletin of the World Health Organization 72: 429-445.
22. Fox-Rushby J, Hanson K (2001) Calculating and presenting disability adjusted life years (DALYs) in cost-effectiveness analysis. Health Policy and Planning 16: 326-331.
23. WHO (2008) Life Tables for WHO Member States (2006). Available: http://www.who.int/whosis/database/life_?tables/life_tables.cfm. Accessed 20 November 2008.
24. Ross A, Penny M, Maire N, Studer A, Carneiro I, et al. (2008) Modelling the Epidemiological Impact of Intermittent Preventive Treatment against Malaria in Infants. PLoS ONE 3: e2661.
25. Smith T, Maire N, Ross A, Penny M, Chitnis N, et al. (2008) Towards a comprehensive simulation model of malaria epidemiology and control. Parasitology 135: 1507-1516.
26. Murray CJL, Lopez AD (1996) Cambridge: MA: Harvard University Press. The global burden of disease: a comprehensive assessment of mortality and disability from diseases, injuries and risk factors in 1990 and projected to 2020; Bank) HSoPHoboWatW, editor.
27. International Drug Price Indicator Guide (2007) Available: http://erc.msh.org/dmpguide/index.cfm?se?arch_cat=yes&display=yes&module=dmp&lang?uage=English&year=2006. Accessed 24 Feb 2009.
28. A joint WHO RBM UNICEF UNAIDS PSI MSH project (2004) Sources and prices of selected products for the prevention, diagnosis and treatment of malaria. Available: http://www.who.int/medicines/areas/acces?s/AntiMalariaSourcesPricesEnglish.pdf. Accessed 24 November 2008.
29. Hutton G, Baltussen R (2005) Cost valuation in resource-poor settings. Health Policy and Planning 20: 252-259.
30. Tan-Torres T, Baltussen R, Adam T, Hutubessy R, Acharya A, et al. (2003) Making choices in health: WHO guide to cost-effectiveness analysis. Available: http://www.who.int/choice/en/. World Health Organization.
31. Johns B, Baltussen R, Hutubessy R (2003) Programme costs in the economic evaluation of health interventions. Cost Effectiveness and Resource Allocation 1: 1.
32. Aponte JJ, Carneiro I, Sanz S, Kobbe R, Loag W, et al. (2009) Pooled analysis of Six IPTi trials with SP. StatisticalWorking Group of the IPTi Consortium.
33. Doubilet P, Begg CB, Weinstein MC, Braun P, McNeil BJ (1985) Probabilistic sensitivity analysis using Monte Carlo simulation. A practical approach. Med Decis Making 5: 157-177.
34. Briggs A, Fenn P (1998) Confidence intervals or surfaces? Uncertainty on the cost-effectiveness plane. Health Economics 7: 723-740.
35. Briggs A, Wonderling D, Mooney C (1997) Pulling cost-effectiveness analysis up by its bootstraps: A non-parametric approach to confidence interval estimation. Health Economics 6: 327-340.
36. Lord J, Asante M (1999) Estimating uncertainty ranges for costs by the bootstrap procedure combined with probabilistic sensitivity analysis. Health Economics 8: 323-333.
37. Shillcutt SD, Walker DG, Goodman CA, Mills AJ (2009) Cost-effectiveness in low- and middle-income countries: A review of the debates surrounding decision rules. Pharmacoeconomics 27: 903-917.
38. Jha P, Mills A, Hanson K, Kumaranayake L, Conteh L, et al. (2002) Improving the Health of the Global Poor. Science 295: 2036-2039.
39. Sachs J (2001) Macroeconomics and Health: Investing in Health for Economic Development. Geneva: World Health Organisation.
40. Adam T, Lim SS, Mehta S, Bhutta ZA, Fogstad H, Mathai M, et al. Achieving the millennium development goals for health: cost effectiveness analysis of strategies for maternal and neonatal health in developing countries. BMJ 2005 331: 1107-10.
41. Morel CM, Lauer JA, Evans DB (2005) Achieving the millennium development goals for health: Cost effectiveness analysis of strategies to combat malaria in developing countries. BMJ 331: 1299.
42. Tan-Torres, Edejer T, Aikins M, Black R, Wolfson L, et al. (2005) Achieving the millennium development goals for health: Cost effectiveness analysis of strategies for child health in developing countries. BMJ 331:
43. World Bank (1993) World Development Report. Washington, DC:
44. WHO (1996) Investing in Health Research and Development. Geneva: World Health Organization. Report of the Ad Hoc committee on health research relating to future intervention options.
45. OANDA (2008) Available: http://www.oanda.com/convert/fxhistory. Historic Currency Converter.
46. WHO CHOICE Available: http://www.who.int/choice/en/. World Health Organisation. Accessed 28 January 2009.
47. Kolaczinski J, Hanson K (2006) Costing the distribution of insecticide-treated nets: a review of cost and cost-effectiveness studies to provide guidance on standardization of costing methodology. Malar J 5: 37.
48. Conteh L, Sharp BL, Streat E, Barreto A, Konar S (2004) The cost and cost-effectiveness of malaria vector control by residual insecticide house-spraying in southern Mozambique: a rural and urban analysis. Trop Med Int Health 9: 125-132.
49. Temperley M, Mueller D, Njagi JK, Akhwale W, Clarke S, et al. (2008) Costs and cost-effectiveness of delivering intermittent preventive treatment through schools in western Kenya. Malar J 7: 196.
50. Mbonye AK, Hansen KS, Bygbjerg IC, Magnussen P (2008) Intermittent preventive treatment of malaria in pregnancy: the incremental cost-effectiveness of a new delivery system in Uganda. Transactions of the Royal Society of Tropical Medicine and Hygiene 102: 685-693.
51. Menendez C, Schellenberg D, Macete E, Aide P, Kahigwa E, et al. (2007) Varying efficacy of intermittent preventive treatment for malaria in infants in two similar trials: public health implications. Malar J 6: 132.
52. Krüger C (2004) Malaria intermittent preventive treatment and EPI coverage. The Lancet 363: 2000-2001.
53. Chandramohan D, Webster J, Smith L, Awine T, Owusu-Agyei S, et al. (2007) Is the Expanded Programme on Immunisation the most appropriate delivery system for intermittent preventive treatment of malaria in West Africa? Trop Med Int Health 12: 743-750.
54. Sculpher MJ, Pang FS, Manca A, Drummond MF, Golder S, et al. (2004) Generalisability in economic evaluation studies in healthcare: a review and case studies. Health Technol Assess 8: 1-192.
55. Brooker S, Kabatereine NB, Fleming F, Devlin N (2008) Cost and cost-effectiveness of nationwide school-based helminth control in Uganda: intra-country variation and effects of scaling-up. Health Policy Plan 23: 24-35.
56. Hutton G, Fox-Rushby J, Mugford M, Thinkhamrop J, Thinkhamrop B, et al. (2004) Examining Within-Country Variation of Maternity Costs in the Context of a Multicountry, Multicentre Randomised Controlled Trial. Applied Health Economics and Health Policy 3: 161-170.
57. Yukich J, Lengeler C, Tediosi F, Brown N, Mulligan J-A, et al. (2008) Costs and consequences of large-scale vector control for malaria. Malaria Journal 7: 258.
58. Barbieri M, Drummond M, Willke R, Chancellor J, Jolain B, et al. (2005) Variability of Cost-Effectiveness Estimates for Pharmaceuticals in Western Europe: Lessons for Inferring Generalizability. Value in Health 8: 10-23.
59. Bognar G (2008) Age-Weighting. Economics and Philosophy 24: 167-189.
60. Trude A, Lydia K (2004) Can the value choices in DALYs influence global priority-setting? Health policy (Amsterdam, Netherlands) 70: 137-149.
61. Phillips M, Phillips-Howard P (1996) Economic implications of resistance to antimalarial drugs. Pharmacoeconomics 10: 225-238.
62. Yeung S, Pongtavornpinyo W, Hastings I, Mills AJ, White NJ (2004) Antimalarial drug resistance, artemisinin-based combination therapy, and the contribution of modeling to elucidating policy choices. Am J Trop Med Hyg 71: 179-186.